(Via fiercebiotech.com) AdaptImmune, a Biotech firm with sites in Oxford  and Philadelphia recently published the early results of a trail of its pioneering cancer immunotherapy treatment. The early indications are so positive it has prompted GlaxoSmithKline to invest $350 million in the company.

Read the full story here.